Stockscreener 앱 받기
3.464
2.60%
0.074
23 Andme Holding Co 주식(ME)의 최신 뉴스
Jane Street Group LLC Sells 1,561,678 Shares of 23andMe Holding Co. (NASDAQ:ME) - MarketBeat
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit's Trusted Technology - The Manila Times
23andMe Launches Discover23 to Help Accelerate Large-Scale - GlobeNewswire
23andMe Launches Discover23 Platform with Massive 4.7B Genetic Data Points for Medical Research - StockTitan
23andMe (NASDAQ:ME) Stock Price Down 0.3%Should You Sell? - MarketBeat
3 Promising US Penny Stocks With Over $9M Market Cap - Yahoo Finance
YourUpdateTV speaks with Marisa Brahney - GlobeNewswire Inc.
23andMe Holding Co. (NASDAQ:ME) Short Interest Down 16.6% in November - MarketBeat
23andMe Stock Price Prediction: 2024, 2025, 2030 - Benzinga
23Andme Holding Co earnings missed by $2.16, revenue topped estimates - Investing.com Nigeria
US Penny Stocks: 3 Picks With Market Caps Under $200M - Simply Wall St
Wojcicki ‘Committed’ to Taking 23andMe Private as Board Quits - MSN
23andMe (NASDAQ:ME) Trading 13.1% HigherHere's Why - MarketBeat
23andMe CEO Anne Wojcicki responds to critics, shares plan for company's future: "Essential for us to restructure" - CBS News
23andMe’s stock falls after company says there’s substantial doubt it can stay in business - MSN
23andMe shares dip as Q2 loss widens despite revenue beat By Investing.com - Investing.com Nigeria
Do Redditors Think That 23andMe Holding Co. (ME) Has a Big Upside Potential? - Insider Monkey
Struggling 23andMe Is Exploring Splitting the DNA Company in Two - MSN
23andMe inks research deal with Mirador Therapeutics By Investing.com - Investing.com Canada
23andMe to slash 40% of its workforce, end therapeutics program to cut costs - MSN
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation - The Manila Times
23andMe inks research deal with Mirador Therapeutics - Investing.com India
23andMe and Mirador Therapeutics Enter Into Strategic - GlobeNewswire
23andMe Partners with Mirador in Major Drug Development Collaboration | ME Stock News - StockTitan
23andMe Holding Co. (ME) Quarterly 10-Q Report - Quartz
Earnings call: 23andMe announces restructuring and focus shift By Investing.com - Investing.com Australia
Earnings call: 23andMe announces restructuring and focus shift - Investing.com
23andMe Holding Co. (NASDAQ:ME) Q2 2025 Earnings Call Transcript - Insider Monkey
23andMe Reports Improved Financial Metrics Amid Revenue Decline - TipRanks
23andMe cuts 40% of its workforce - Fox Business
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs - Yahoo Finance
23andMe’s stock turns lower after company posts its latest quarterly loss - MSN
23andMe cuts 40% of its workforce, discontinues all therapy programs - Reuters
23andMe to Explore Strategic Alternatives - Marketscreener.com
23andMe Holding Co Reports Q2 FY25 Revenue of $44 Million, Missi - GuruFocus.com
23andMe Holding Co. (ME) Misses Q2 EPS by 216c - StreetInsider.com
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results - GlobeNewswire
23andMe Holding Co. Announces Reduce Overall Headcount - Marketscreener.com
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future - The Manila Times
23andMe Announces Business Restructuring to Streamline - GlobeNewswire
23andMe Cuts 40% of Workforce, Exits Therapeutics in Major Cost-Saving Overhaul | ME Stock News - StockTitan
Earnings Outlook For 23andMe Holding - Benzinga
Federal law could prevent your 23andMe data deletion, but you should still try - Android Police
CORRECTION23andMe to Report Q2 FY2025 Financial Results - The Manila Times
23andMe Revises Q2 FY2025 Earnings Release Time to Pre-Market on Nov 12 | ME Stock News - StockTitan
0.97%
자본화:
|
볼륨(24시간):